813 results
Page 4 of 41
SC TO-T/A
EX-99
jyh8yjy
26 Apr 23
Third party tender offer statement (amended)
6:16am
6-K
EX-99.1
vt1w h2es
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.2
mw4y1on anxej
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
jkx14cek aaf14end2
11 Apr 23
Current report (foreign)
1:02pm
SC TO-T/A
EX-99
cu8xr9qe 3sdiktelc
10 Apr 23
Third party tender offer statement (amended)
4:38pm
6-K
EX-99.3
2zzt86bvt33ofghz
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
ralr24vtwjay
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.2
2cl4fgpehtcio6jcq0
20 Dec 22
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for prurigo nodularis
6:13am
6-K
EX-99.1
xxqpevdhnb1w
2 Dec 22
Positive Phase II/III study results support acoziborole’s potential in treatment for deadly disease
10:40am
6-K
EX-99.1
p6hiqsms8m1 ulac7
21 Nov 22
European Commission approves Enjaymo® (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease
10:05am
6-K
EX-99.2
9j7l62rjewtb1b8m
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
zg0pi6 4i
15 Nov 22
Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission
3:01pm
6-K
EX-99.1
psylecucjbh
10 Nov 22
European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
2:00pm
6-K
EX-99.1
v5pc6o
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
f6pu4
17 Oct 22
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
1:35pm
6-K
EX-99.1
hm1n50 5d9
3 Oct 22
Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis
11:24am
6-K
EX-99.1
5k95mdz 73
22 Sep 22
CHMP recommends approval of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
9:49am
6-K
EX-99.2
z7hm0in vy5k
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.3
h1q23zzd6j0
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.1
eymx1u7d5crsrr
12 Sep 22
Evolution of the Board of Directors
7:07am